InvestorsHub Logo
Followers 23
Posts 1907
Boards Moderated 0
Alias Born 12/14/2009

Re: None

Wednesday, 06/12/2013 11:11:58 AM

Wednesday, June 12, 2013 11:11:58 AM

Post# of 9288
Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study of two Phase III trials that compared its Lymphoseek radiopharmaceutical injection with a commonly used agent. Lymphoseek "demonstrated reliable detection of lymph nodes" in patients with breast cancer and melanoma over a period of 15 minutes up to 30 hours, a time range that may be encountered in a clinic. (PR)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NAVB News